Login / Signup

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.

Ramin Sedaghat HeratiDavid A KnorrLaura A VellaLuisa Victoria SilvaLakshmi ChilukuriSokratis A ApostolidisAlexander C HuangAlexander MuselmanSasikanth ManneOliva KuthuruRyan P StaupeSharon A AdamskiSenthil KannanRaj K KurupatiHildegund C J ErtlJeffrey L WongStylianos BournazosSuzanne McGettiganLynn M SchuchterRitesh R KotechaSamuel A FuntMartin H VossRobert J MotzerChung-Han LeeDean F BajorinTara C MitchellJeffrey V RavetchE John Wherry
Published in: Nature immunology (2022)
Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell responses in patients with cancer but PD-1 is also expressed by other immune cells, including follicular helper CD4 T cells (Tfh) which are involved in germinal centre responses. Little is known, however, about the effects of anti-PD-1 immunotherapy on noncancer immune responses in humans. To investigate this question, we examined the impact of anti-PD-1 immunotherapy on the Tfh-B cell axis responding to unrelated viral antigens. Following influenza vaccination, a subset of adults receiving anti-PD-1 had more robust circulating Tfh responses than adults not receiving immunotherapy. PD-1 pathway blockade resulted in transcriptional signatures of increased cellular proliferation in circulating Tfh and responding B cells compared with controls. These latter observations suggest an underlying change in the Tfh-B cell and germinal centre axis in a subset of immunotherapy patients. Together, these results demonstrate dynamic effects of anti-PD-1 therapy on influenza vaccine responses and highlight analytical vaccination as an approach that may reveal underlying immune predisposition to adverse events.
Keyphrases